Alligator Bioscience Q4 2024: Can the Rights Issue Fund Alligator to a Deal? - Redeye

Redeye comments on Alligator Bioscience's Q4 report and the rights issue, which was subscribed to 54%. This means no guarantee commitments will be utilised. Mitazalimab is close to reaching phase III readiness. The key element missing is funding, which has to come from a partner.

Länk till analysen i sin helhet: https://www.redeye.se/research/1068969/alligator-bioscience-q4-2024-can-the-rights-issue-fund-alligator-to-a-deal?utm_source=finwire&utm_medium=RSS